Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30379% above fair value
$15.71−0.15 (-0.95%)
Close on Nov 13, 2026Market cap $1.68BP/E –Yield –
Personalis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Personalis's ebitda for the twelve months ending Sep 30, 2026 was -$116.81M. For fiscal 2025 it was -$78.01M. The highest annual figure on record is -$10.70M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$78.01M | – |
| FY2024 | Dec 31, 2024 | -$57.33M | – |
| FY2023 | Dec 31, 2023 | -$98.64M | – |
| FY2022 | Dec 31, 2022 | -$107.10M | – |
| FY2021 | Dec 31, 2021 | -$59.34M | – |
| FY2020 | Dec 31, 2020 | -$36.39M | – |
| FY2019 | Dec 31, 2019 | -$17.67M | – |
| FY2018 | Dec 31, 2018 | -$10.70M | – |
| FY2017 | Dec 31, 2017 | -$20.95M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$33.04M | – |
| Q2 FY2026 | Jun 30, 2026 | -$31.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.99M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.19M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.15M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.10M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.38M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -$851.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.01M | – |
See a number that looks wrong?